Carisma Therapeutics, Inc.
CARM
$0.2153
$0.00180.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -38.84% | -13.80% | 41.18% | 9.45% | 2.08% |
| Total Depreciation and Amortization | -9.23% | 189.02% | -84.94% | 134.49% | 3.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.79% | -44.63% | 37.98% | 32.75% | -2.80% |
| Change in Net Operating Assets | 355.57% | 65.06% | -14.07% | -476.08% | 187.12% |
| Cash from Operations | 35.85% | 19.23% | 28.12% | -39.31% | 23.34% |
| Capital Expenditure | -- | 100.00% | -523.53% | 96.97% | -196.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -63.33% |
| Cash from Investing | -- | 100.00% | -523.53% | -100.16% | -64.98% |
| Total Debt Issued | -- | -- | -100.00% | -- | -100.00% |
| Total Debt Repaid | -1.19% | -930.99% | 104.38% | -174.45% | 60.01% |
| Issuance of Common Stock | -- | 6,350.00% | -99.91% | 230.64% | 1,630.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -34.49% | -731.51% | -94.60% | 1,238.61% | 104.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.45% | 16.54% | 23.41% | -279.52% | -181.97% |